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ABSTRACT 
Antibiotic resistance is a growing problem as microorganisms exhibiting resistance to antibiotics 
of last resort have been reported in hospitals around the world. To respond to this problem, it is 
necessary to develop and discover novel antibacterial compounds. A rich reservoir of antibacterial 
compounds are microbial secondary metabolites, a structurally diverse group of molecules 
produced by microbes in response to changing environmental conditions providing some 
advantage to their producers. Particularly prolific producers of these compounds are bacteria of 
the group Streptomyces, these being responsible for a large portion of the naturally sourced 
antibacterial compounds used today. In order to access novel and untapped chemical diversity, the 
investigation of unexplored biological niches has become more prevalent, with the study of cave 
dwelling microorganisms producing promising leads. This study examines the antimicrobial 
secondary metabolites produced by three cave Streptomyces strains S1, S4, and PM58b for their 
previously described activity against target multi-drug resistant Escherichia coli and methicillin 
resistant Staphylococcus aureus with the goal of determining their molecular characteristics. To 
achieve this, three strains of Streptomyces were grown for periods of 10 to 30 days to induce the 
production of secondary metabolites. Bioactivity was confirmed in S1 and S4 by an agar-plug 
assay and was observed as a pigmented ring of inhibition after an extended period of incubation. 
Streptomyces strain S1 fermentation broth was extracted and analyzed by matrix assisted laser 
desorption ionization mass spectrometry for the preliminary identification of the antimicrobial 
compound present. Antimicrobial activity could not be isolated in a cell free environment from S1 
fermentation broths; instead, the antimicrobials were produced on the assay plate. Differences 
were observed between the fermentation broth and sterile media mass spectra; however, a 
molecular mass could not be assigned to the putative antimicrobial compound. 
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INTRODUCTION 
Antibiotic resistance 
 The progressive spread of antibiotic resistance among pathogenic bacteria is a dire problem 
to which no clear solution has arisen, to the growing concern of public health authorities, 
governments, and medical professionals alike. The spread of these antibiotic resistant phenotypes 
is a clear example of artificial selection. This selective pressure is established as a consequence of 
the extensive use of antibiotics in agriculture, medicine, and daily life leading to the evolution of 
resistant strains of bacteria. Shortly after the advent of the widespread therapeutic use of antibiotics 
with the discovery and application of penicillin, antibiotic resistance has followed close behind 
with resistant strains becoming more and more prevalent (Davies and Davies 2010). The 
mechanisms underlying this resistance vary between the intrinsic resistances some groups of 
pathogenic microbes display to certain classes of antibiotics, to acquired resistances developed 
over time in response to the selective pressure placed on pathogenic bacteria due to the application 
of antibiotics (Blair et al 2015). Examples of these acquired resistances are drug efflux systems, 
antibiotic modifying enzymes, and changes to the cellular target itself (Blair et al. 2015). Adding 
to the problem of the emergence of antibiotic resistance is its capacity to spread between bacteria 
through the horizontal transfer of chromosomal and extrachromosomal genetic material leading to 
the emergence of multi-drug resistant (MDR) strains of bacteria (Cohen et al. 1972; Blahna et al. 
2006; Davies and Davies 2010). In order to combat this spread of antibiotic resistance a 
multifaceted approach must be implemented through new restrictions on the availability and 
approved uses of existing antibiotics, the development of new analogues of existing antibiotics, 
and through the exploration of novel chemical space to identify new antibiotic compounds with 
both unique molecular scaffolds and mechanisms of action (Davies and Davies 2010).  
The Streptomyces lifecycle and the production of secondary metabolites 
 Streptomyces have historically been a prolific microbial source of antimicrobial secondary 
metabolites, producing many of the antibiotics on the market today. These typically soil dwelling 
bacteria are Gram positive and undergo a complex life cycle, moving between vegetative and aerial 
hyphal states. Streptomyces grow from single spores into branching vegetative hyphae that 
elongate by apical tip extension forming a substrate mycelium (Sigle et al. 2015, Flardh and 
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Buttner 2009). Responding to environmental cues such as nutrient depletion, the Streptomyces 
undergo a morphological differentiation producing aerial hyphae during which the secondary 
metabolism associated with the production of antimicrobial compounds is activated (Flardh and 
Buttner 2009; Sigle et al. 2015). 
 The production of antimicrobial secondary metabolites in Streptomyces is regulated by a 
variety of factors, and the synthesis of these compounds can be induced in response to multiple 
stimuli. The presence of stimulatory precursor molecules can have an inductive effect on the 
synthesis of these secondary metabolites, as observed in the impact of lysine on the synthesis of 
cephamycin C in S. clavuligerus, or the role of valine in the synthesis of tylosin in S. fradiae 
(Nguyen et al. 1995; Demain 1998; Leite et al. 2013,). The synthesis of these antimicrobial 
compounds can also be due to the activity of endogenous auto-regulator molecules. These auto-
regulatory compounds take several forms one of which are the γ-butytrolactones. These 
compounds act as ligands to cytoplasmic regulatory proteins such as ArpA in S. griseus, binding 
and deactivating them, preventing their binding of the Streptomyces chromosomal DNA and 
fulfilling their role as repressors (Takano 2006). In S. griseus this ArpA deactivation allows for 
the synthesis of AdpA, a regulatory protein responsible for both the upregulation of the synthesis 
of secondary metabolism as well as the morphological differentiation of the bacteria (Bibb 2005). 
The morphological changes observed with activation of AdpA are the formation of aerial hyphae 
and their subsequent sporulation, a process promoted by lowered ATP levels. (Wolanski et al. 
2012). The production of these autoregulatory compounds such as γ-butytrolactones are controlled 
by biosynthetic genes typically located nearby biosynthetic clusters responsible for secondary 
metabolites synthesis (Bentley et al. 2002; Liu et al. 2013).  
Other regulators in the production of secondary metabolites include the alarmone 
guanosine pentaphosphate (p)ppGpp, which in response to stresses such as heat shock or nutrient 
deprivation, modulates cellular metabolism and transcription in a concentration dependant manner 
initiating the stringent response (Hauryliuk et al. 2015). The cytosolic (p)ppGpp concentration is 
regulated by the ribosome associated enzyme Re1, which directly monitors the process of 
translation within the cell. When exposed to stress inducing conditions such as nutrient deprivation 
(p)ppGpp is synthesized, which through direct or indirect mechanisms, downregulates the 
production of ribosomal proteins while promoting the biosynthesis of amino acids and genes 
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associated with stationary phase processes such as secondary metabolism (Hesketh et al. 2007; 
Hauryliuk et al. 2015). 
Accessing novel chemical diversity 
Although the chemical diversity of Streptomyces secondary metabolism has been the 
subject of intense study, leading to the discovery of a multitude of anticancer, antifungal, and 
antibiotic compounds, science still has much to gain from further investigation of this genus. 
However, in order to achieve this goal scientists must employ new approaches and technologies. 
Through the development and application of metagenomic approaches to drug discovery, the 
identification of potential antimicrobial secondary metabolites through the detection and analysis 
of biosynthetic clusters associated with secondary metabolism progress has led to the discovery of 
new antimicrobial secondary metabolites (Handelsman 2004, Seipke 2015, Chu et al. 2016). In 
addition to these wide-net approaches to the discovery of new microbial sources of antibiotics, the 
exploration of new and understudied microbial niches such as the ocean or caves allows 
researchers to access new species of Streptomyces and potentially novel antibiotic secondary 
metabolites (Fielder et al. 2005, Cheeptham et al. 2013, Rateb et al. 2011). These understudied 
niches often represent extreme environments, with the cave environment being a clear example of 
this; having low levels of readily available organic carbon, little to no light, and high mineral and 
salt content (Ghosh et al. 2016). In these extreme environments, endogenous bacteria have evolved 
metabolic processes to access the limited resources available to them, which along with the rich 
diversity in the cave environment, contributes to the development of unique often species specific 
secondary metabolites (Bhullar 2012, Cheeptham et al. 2013, Cuezva et al. 2012). This study aims 
to explore the potentially novel chemical diversity associated with cave Streptomyces through the 
molecular characterization of previously described antimicrobial activity ascribed to Streptomyces 
strains isolated from Iron Curtain Cave near Chilliwack B.C. (S1 and S4) and from Helmcken Falls 
Cave in Wells Gray Provincial park near Clearwater B.C (PM58b). Helmcken Falls Cave has been 
extensively studied being identified as volcanic in origin, with subsequent modifications 
introduced through the activity of the nearby Murtle and Clearwater Rivers. The cave 
macroenvironment of Helmcken Falls Cave includes basalt walls and ceilings as well as deposits 
of fine sands and sediments (Cheeptham et al. 2013). Iron Curtain Cave located near Chilliwack 
B.C. although not nearly as well studied, is also a cave of volcanic origin (Mason et al. 2015).  
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MALDI as a tool for the preliminary structural elucidation of secondary metabolites 
In order to proceed with the drug discovery process, from the identification of an organism 
exhibiting antimicrobial activity, to the application of the bioactive compound in a clinical 
environment, the complete structural elucidation of the compound is necessary. A crucial step in 
this process is the determination of the molecular mass of the compound of interest by mass 
spectrometry, as this step facilitates further investigation by techniques such as IR and NMR, 
allowing for complete structural elucidation (Kind and Fiehn 2010). Mass spectrometry in 
conjunction with elemental analysis techniques such as energy dispersive X-ray spectroscopy, 
allows for the identification the molecular formula of the compound of interest and thus permits 
future studies of the connectivity and functionality of the compound by NMR and IR experiments 
(Kind and Fiehn 2010). In addition to this, dual mass spectroscopy (MS-MS) itself can be used to 
derive structural information of the compound of interest through its sequential and the prediction 
of fragmentation patterns (Cabrera 2006).  
Matrix assisted laser desorption ionization (MALDI) is a form of mass spectrometry that 
is typically used to analyze large molecules such as whole proteins or peptides. Although 
conventionally applied to these larger molecules, MALDI remains a valuable instrument in the 
analysis of smaller molecules such as those secondary metabolites being produced by 
Streptomyces (Cohen and Gusev 2002). MALDI-MS boasts high sensitivities and high mass 
resolutions while also being a high throughput technique allowing for the rapid analysis of many 
samples. In addition to this, MALDI is a soft ionization technique resulting in little to no 
fragmentation of target compounds. The consequence of this being, instead of producing charged 
fragments MALDI-MS tends to ionize the whole compound producing a quasi molecular ion 
(MH+) peak, providing information on the molecular weight of the compound allowing for greater 
ease the determination of the compound’s molecular formula. Although it benefits from being a 
high throughput technique capable of achieving high resolutions and sensitivities, MALDI suffers 
from the detection of matrix peaks at low m/z values such as those examined in this experiment 
(Cohen and Gusev 2002). In addition to this MALDI cannot be coupled directly to a 
chromatography column, preventing any separation of the compounds in the sample of interest 
prior to ionization. These problems can be addressed through the introduction of an ionization 
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suppressant such as cetyltrimethylammonium bromide (CTAB) and conducting a preparatory 
separation by column chromatography (Guo et al. 2002). 
Experiment goals and approach 
Using liquid-liquid extraction and MALDI-MS, this study aims to identify the 
antimicrobial secondary metabolites of cave Streptomyces strains S1, S4, and PM58b by assigning 
a molecular mass to these compounds. This is achieved by the nutrient deprivation of mature 
Streptomyces cultures through the growth of these bacteria in batch culture until fermentative 
conditions are achieved. The presence of antimicrobial activity is then to be confirmed through 
plug diffusion assays against multi-drug resistant and laboratory strains of S. aureus and E. coli. 
Once antimicrobial activity is established in the Streptomyces fermentation broths, liquid-liquid 
extraction of the responsible metabolite will be attempted with a variety of organic solvents, after 
which antimicrobial activity will be confirmed by further bioassays. Low m/z mass spectra will be 
obtained for these extracts and the original fermentation broths through MALDI-MS and 
antimicrobial activity will be correlated to the emergence and persistence of novel signals in the 
MS spectra.  
MATERIALS AND METHODS 
 
Figure 1. Overview of experimental approach to the production and analysis of antimicrobial activity of cave Streptomyces strains 
S1, S4, and PM58b. 
Growth Conditions for 
Streptomyces strains S1, 
S4, and PM58b established 
in R2A, V8, and Hickey 
Tresnar growth media
Fermentative conditions 
established through the 
nutrient limitation of 
Streptomyces bacterial 
cultures
Plug diffusion assays 
carried out to establish 
antimicrobial activity of 
Streptomyces fermentation 
broths against E. coli, 
MDR E. coli, S. aureus, 
and MRSA
Perform solvent 
extractions on  
Streptomyces fermentation 
broth and analyze these 
extracts using MALDI 
mass spectrometry
Correlate the presence of 
antimicrobial compounds 
in fermentation broth 
extracts to specific peaks 
on mass spectra. 
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Growth of Cave Streptomyces Cultures 
Streptomyces strains S1 and S4 were streaked for isolated colonies from stock plates onto 
Hickey-Tresnar (HT) Agar using aseptic technique and were then grown at 8°C and 15°C. These 
HT plates served as stock plates for work done using S1 and S4 in this experiment and were stored 
under refrigeration at 4°C. Isolated colonies of S1 and S4 were then aseptically transferred from 
these stock plates into 16x100 mm glass test tubes containing sterile 3 mL of R2A (S1) and V8 
(S4) broth. Ten 3 mL cultures of each strain were prepared in this manner. From the twenty S1 
and S4 cultures five of each strain were then grown at temperatures of 8°C and 15°C in shaking 
incubators for a period of 10 days. Following this period, the strains were assessed for 
antimicrobial activity, and analyzed by MALDI. These cultures were evaluated before conducting 
bioassays by Gram staining to ensure no contamination had occurred. 
Following these growth and antimicrobial activity assays S1 and S4 were grown at 8°C for 
durations up to 30 days under the above described conditions. These strains were then assessed for 
antimicrobial activity. Following this a 300 mL volume of sterile R2A broth was inoculated with 
S1 using 1.00 mL of a 3 mL five-day culture. This culture was incubated at 8°C for a period of 30 
days after which extractions, bioassays for antimicrobial activity and mass spectrometry analyses 
were performed. 
 Streptomyces strain PM58b was streaked for isolated colonies from a stock culture 
suspended in 30% glycerol stored at -20°C onto a HT agar plate where it was then grown at 8°C 
and 15°C. This HT plate served as a stock plate for the work done using PM58b for this study. The 
plate was stored under refrigeration at 4°C Isolated colonies were then aseptically transferred from 
the stock plate into16x100 mm glass test tubes containing sterile 3mL HT broth. These PM58b 
cultures were similarly fermented for durations of 10 to 30 days at temperatures of 8°C and 15°C 
after which the broth was bioassayed for antimicrobial activity. 
Bioassays for Antimicrobial Activity 
 The Streptomyces strains were evaluated for antimicrobial activity using a plug diffusion 
assay described by S. Ghosh in a personal communication (2016). This assay was prepared using 
sterilized 225x225 mm polystyrene bioassay plates. These plates were sterilized using 1.5% 
Peroxyguard solution, 70% ethanol, and UV light exposure for a duration of 20 minutes. Following 
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this, 250 mL of autoclaved molten nutrient agar maintained at a temperature of 55°C was 
inoculated to give a concentration of 1x106 cells per mL of the target organism, and was delivered 
to the plate and allowed to solidify. The target organisms used for these assays were laboratory 
and drug resistant strains of S. aureus (MRSA-43300) and E. coli (15-104, 15-124, 15-318) which 
were provided by LifeLabs (Kamloops B.C.). Isolated colonies of these organisms were aseptically 
transferred from blood agar stock plates to 3 mL volumes of nutrient broth. These cultures were 
then incubated with shaking 100 rpm for a duration of 20-24 hours. The concentration of cells in 
the 3mL culture was then quantified by measuring the culture’s optical density (OD). This was 
done using a Pharmacia NovaSpecIII Spectrophotometer set at a wavelength of 600 nm and 
Plastibond 1.5 mL cuvettes to which 1.00 mL of culture was added. The spectrophotometer was 
blanked using sterile nutrient broth, after which OD measurements of the culture being assayed 
were made in triplicate. An average OD was taken, and using the assumption that an OD of 1.0 
corresponds to a cellular concentration of 8x108 cells per mL, a volume of the 3 mL stock culture 
was delivered using a p1000 VWR micropipette and sterile disposable pipette tips to the molten 
agar to give a final concentration of 1x106 cells per mL in the nutrient agar. The nutrient agar was 
then delivered to the plate and allowed to solidify. Once the agar had solidified plugs were bored 
out of the agar using a flame sterilized bore with a 6 mm ID, producing wells with a volume of 
100 µL. To these wells 100 µL of the material being assayed was delivered using a p200 VWR 
micropipette. As positive controls 100 µL volumes of Peroxyguard and 70% ethanol were used. 
For drug resistant organisms 6mm diameter diffusion disks impregnated with 30 µg of tetracycline 
produced by Beeton Dickinson and Company were used also used. Bioassay plates were incubated 
at 37°C, 25°C, and 15°C for a duration of 7 days, activity was evaluated daily. 
 Alongside the various growth conditions assayed, assays were performed with 
fermentation broth supernatant samples, filtrate samples, heat shocked samples, and extracts. 
Supernatant samples were prepared by transferring 1.00 mL volumes of Streptomyces culture to 
autoclaved 1.5 mL Eppendorf tubes which were subsequently centrifuged at 14,000 rpm for a 
duration of 10 minutes on a Hermle Z 233 MK-2 Centrifuge. From these Eppendorf tubes 0.500 
mL of the supernatant was then transferred to fresh, sterile 1.5 mL Eppendorf tubes from which it 
was delivered to the assay plate. Heat shocked samples were prepared by delivering 1.00 mL 
volumes of the Streptomyces broth to autoclaved 1.5 mL Eppendorf tubes which were then placed 
in a boiling water bath for a duration of 10 minutes. Filtered samples were obtained for S1 samples 
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by first centrifuging 1.00 mL volumes of fermentation broth as described above. The supernatants 
of these 1.00 mL volumes were then delivered to a sterile 5.0 cc Luer lock syringe using a p1000 
VWR micropipette and was subsequently filtered through a 0.45 µm VWR cellulose acetate luer 
lock filter into sterile Eppendorf tubes from which the filtrate was delivered to the assay plate. 
Finally extract samples were prepared by centrifuging 30 mL volumes of the Streptomyces culture 
in 50 mL VWR pre-sterilized plastic centrifuge tubes at 5000 rpm in an IEC MP4 Centra 
centrifuge. The supernatant from these tubes was then poured through a 70µm nylon mesh Fischer 
Scientific cell strainer in to an autoclaved 250mL volumetric flask. Of this cell free filtrate 50 mL 
was measured out and transferred using a graduated cylinder into a 250 mL separatory funnel. 
Several extractions were performed, with the first using three 10 mL volumes of LC-MS grade 
hexane followed by three 10 mL volumes of LC-MS grade ethyl acetate. The fractions were 
combined and the solvents were evaporated in evaporating dishes under the fume hood. Upon the 
evaporation of the solvents the residues were dissolved in 2.00 mL of autoclaved 18 MΩ water, of 
which 1.5 mL was transferred into autoclaved Eppendorf tubes. Extractions were also attempted 
on the 70 µm filtrate using three 10 mL volumes of LC-MS grade ethyl acetate which was then 
similarly evaporated in the fumehood and subsequently dissolved in 2.00 mL of autoclaved 18 MΩ 
water. 
MALDI Sample Preparation 
Samples were prepared on a ground steel target plate for analysis by MALDI. The samples 
were prepared as per the dried droplet protocol described by Bruker Daltonics MALDI preparation 
protocols. Equal volumes of the fermentation broth sample and TA30 (30:70 (v/v) acetonitrile 
:0.1% trifluoracetic acid in 18 MΩ water) saturated with α-cyano-4-hydroxy cinnamic acid 
(HCCA) were premixed in a clean sterile Eppendorf tube. From this Eppendorf tube 1 µL of the 
sample-matrix solution was delivered directly to the ground steel plate. To ensure the spectra 
obtained were consistent and representative of the sample solution, fermentation broth samples 
were run in replicates of 6. The samples analyzed in this manner included, Sterile R2A, and 30 
day S1 fermentation broth filtrate 
MALDI Sample Analysis 
Samples were analyzed using a Bruker MicroFlex LRF MALDI. The method used for this 
analysis was developed and implemented using Bruker Daltonics flexControl software (version 
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3.3.108.0). Compounds of m/z’s of 0 Da to 4000 Da were selected and evaluated with the response 
limited to a signal-to-noise threshold of 6.0 and over, a maximal peak number of 300, a maximal 
peak width of 0.2 m/z and a resolution higher than 100. Noise was reduced using a Tophat baseline 
subtraction algorithm. The sample and matrix were ionized using a 19.99 kV ion source with the 
laser set on the random walk setting. Samples were analyzed by summing up 800 satisfactory shots 
taken in 80 shot steps using a 60 Hz laser starting at 20% power before reaching maximal power 
at 80% power. The resultant spectra were analyzed using Flex Analysis software. Mass-to-charge 
values were copied into Microsoft Excel and the m/z values of the 30 day S1 fermentation broth 
were screened for peaks observed consistently in 2 or more of the 6 replicates analyzed within a 
difference of 0.005 m/z. These consistently observed peaks were then screened against all peaks 
observed in any of the R2A background spectra to identify signals present in the 30 day S1 
fermentation broth but not present in the R2A background spectra. 
RESULTS 
Growth of Cave Streptomyces Cultures 
Strains S1, S4 and PM58b were observed to grow effectively at temperatures of 8°C and 
15°C, growing faster at the 15°C condition. On HT agar S1 grew into large white filamentous 
colonies, S4 grew into flat gray filamentous colonies, and PM58b grew into large raised white 
filamentous colonies. In R2A broth S1 formed rounded filamentous pellet-like colonies, forming 
strand like structures on the walls of the test tube. S4 growing in V8 broth was observed to form 
smaller flocculant, forming filamentous strand like structures on the walls of the test tube. PM58b 
formed white filamentous colonies in HT broth forming strand like structures on the walls of the 
test tube. In all three cultures, growth was evaluated visually as the pellet and flocculant nature of 
the Streptomyces strains prevented optical density measurements and made dilution and plating 
approaches non-representative of the actual number of cells in the culture. As the fermentation 
broths aged, S1 and S4 cultures developed a brown pigmentation which became more pronounced 
as the culture grew older; this pigmentation was not observed in PM58b. 
Bioassays for Antibacterial Activity 
Antimicrobial activity was observed in S1 and inconsistently in S4 against S. aureus, E. 
coli, MRSA and MDR E. coli. No antimicrobial activity was observed in the PM58b fermentation 
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broth. The antimicrobial activity was observed after a 10 day fermentation period up until 30 days 
of fermentation in S1, beyond which assays were not performed. In S4 activity was only observed 
after an extended period of nutrient limitation, with the effects being observed after a 30 day 
fermentation. Antimicrobial activity presented in both strains as a zone of inhibition surrounding 
the plug to which the fermentation broth was delivered. In addition to being devoid of the 
cloudiness characteristic of growth of the target organisms, these zones of inhibition were 
pigmented a dark brown. In the plug holes from which these regions of antimicrobial activity 
radiated from, Streptomyces growth was observed. This antimicrobial activity was observed when 
the bioassay plates were incubated at 15°C however this activity was not present when higher 
temperatures (37°C) were used. The antimicrobial activity developed over the duration of the 
incubation of the bioassay plate with activity first appearing as a small pigmented zone of 
inhibition after day 2, and developing into a larger clearer pigmented zone of inhibition after day 
7. Antimicrobial activity was observed in the supernatants of S1 and S4; however, this activity 
was accompanied with growth of the Streptomyces on the walls of the plug holes. Antimicrobial 
activity was not observed in heat shocked samples in either strain. Antimicrobial activity was also 
not observed in the 0.35 µm filtered S1 fermentation broth. Neither the hexane nor the ethyl acetate 
extracts exhibited antimicrobial activity against the target organisms. Similarly, when the aqueous 
fraction of the extracted broth was tested, no activity was observed. When assays were performed 
with the unextracted fermentation broth supernatant, which had previously only been filtered 
through a 70 µm cell strainer antimicrobial activity was observed along with growth of S1 within 
the agar plug hole. 
Table 1. Compiled observations of antimicrobial activity of S1, S4 and PM58b at 15°C incubation temperatures under varying 
treatments. (+) designates bioactivity observed, (-) designates no bioactivity observed, and NA indicates that the combination of 
strains and treatments indicated were not tested. 
Strain 8 
day 
10 day 30 day  
Super
natant 
0.35µm 
Filtrate 
Ethyl 
Acetate 
Extract 
Hexane 
Extract 
Aqueous 
Fraction 
70µm 
strained 
broth 
Heat 
Shock 
S1 + + + + - - - - + - 
S4 - - + + NA NA NA NA NA - 
PM58
b - - - - NA NA NA NA NA - 
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Figure 2. Antimicrobial activity plug assay of S1 and S4 fermentation broths grown for 8 and 30 day durations at 8°C against 
laboratory strains of E. coli and S. aureus. Plates were incubated at 37°C for a 7 day period 
 
Figure 3. Antimicrobial activity plug assay of S1 and S4 fermentation broths grown for 8 and 30 day durations at 8°C against 
laboratory strains of E. coli and S. aureus. Plates were incubated at 15°C for a 7 day period 
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Figure 4. Antimicrobial activity plug assay of S1, S4, and PM58b fermentation broths grown for 10 and 30 day durations at 8°C 
and 15°C against a laboratory strain and MDR E. coli. Plates were incubated at 15°C for a 7 day period. 
 
Figure 5. Antimicrobial activity plug assay of S1, S4, and PM58b fermentation broths grown for 10 and 30 day durations at 8°C 
and 15°C against a laboratory strain of S. aureus and MRSA. Plates were incubated at 15°C for a 7 day period. 
MALDI Analysis of Fermentation Broth, and R2A Background 
From the comparison of the R2A background and the 30 day S1 fermentation broth 25 
consistently observed signals were identified as being present in the fermentation broth but absent 
in the R2A background spectra. These unique signals ranged from 236.881 to 623.675 m/z. These 
signals were tabulated in the Appendix. 
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DISCUSSION 
The results of the accumulated bioassays conducted using S1 indicate that the fermentative 
conditions previously described failed to elicit antimicrobial activity in the cell free fermentation 
broth. No antimicrobial activity was observed when Streptomyces cells were not present or failed 
to thrive in the plugs of the bioassay plate. This lack of activity in the absence of cells was indicated 
by the results obtained from filtering the supernatant of the 30 day S1 fermentation broth through 
a 0.35 µm cellulose acetate filter. This filtration removed the Streptomyces cells, leaving an 
inactive cell free aqueous fermentation broth. This result pointed towards the bioactive compound 
responsible for the antimicrobial activity observed in bioassays of the cell containing culture being 
absent or present in concentrations too low to have an observable effect in the cell free broth. This 
was partially supported by the results of bioassays conducted using heat shocked supernatant. The 
heat shocking of the Streptomyces fermentation broth at 100°C for 10 minutes likely killed the 
majority of cells persisting in the supernatant leading to no Streptomyces growth on the bioassay 
plate and therefore no antimicrobial activity. However, the treatment that killed the Streptomyces 
present in the supernatant may have also degraded the antimicrobial compound, leading to a loss 
of bioactivity and making this result inconclusive on its own. More direct support for the 
conclusion that the antimicrobial compound was not substantially present in solution are the results 
of assays conducted using the re-dissolved residues of organic extracts and the aqueous component 
of the organic extract. The extraction of a 50 mL volume of strained S1 fermentation broth 
supernatant using both hexane and ethyl acetate likely killed any persister cells in the broth, leading 
to no live Streptomyces in the re-dissolved organic residue or in the aqueous fraction. While this 
treatment likely killed the persisting Streptomyces cells it would have had minimal impact on any 
potentially bioactive compounds in solution, and should have concentrated any that partitioned 
into the ethyl acetate or hexane fractions. Assaying these re-dissolved extracts, the aqueous 
fraction they were extracted from and an unextracted portion of the strained fermentation broth 
supernatant showed no antimicrobial activity but for the unextracted broth after an extended 
incubation. This indicates that the antimicrobial compound of interest was not produced in solution 
and was instead being produced on the bioassay plate. The antimicrobial activity exhibited by 
Streptomyces strain S4 presented in a similar manner as S1, showing activity against E. coli and 
S. aureus, in conjunction with the spread of dark brown pigment that developed and spread over 
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time. The antimicrobial activity attributed to S4, however, was obtained inconsistently, occurring 
in only two separate sets of bioassays in which 30-day old small test tube scale fermentation broths 
were used. This inconsistency and loss of activity when the process was scaled up to larger 
volumes prevented further exploration of the antimicrobial activity. PM58b exhibited no activity 
at all in this experiment, which similarly prevented further exploration. 
Observations on the effects of the incubation conditions and duration on the antimicrobial 
activity of S1 indicate that the antimicrobial compound was produced on the plate. Firstly, the 
development of antimicrobial activity over the duration of the incubation of the bioassay plates 
indicates that the compound was produced in increasing concentrations on the bioassay plate as 
the Streptomyces present grew and developed. The degree of antimicrobial activity was observed 
to progress over time increasing in intensity and in the radius of the zone of inhibition. This 
observation contrasted sharply with the behaviour of the positive controls; Peroxyguard and 
tetracycline, which involved finite amounts of each compound, and presented as clearly delineated 
zones of inhibition that developed shortly after the delivery of the control to the bioassay plate. 
The lack of antimicrobial activity at 37°C despite the presence of Streptomyces cells in the bioassay 
wells supports the idea that the antimicrobial compound is produced on the plate as a result of 
Streptomyces cells growth. This is because the cave Streptomyces S1were unable to grow at the 
37°C incubation temperature, and as such the antimicrobial was not produced. Despite not being 
secreted into the fermentation broth, the progressive diffusion displayed by the antimicrobial 
compounds produced by S1 suggests that the antimicrobial compound was secreted and not surface 
bound to the microbe as Streptomyces are non-motile organisms. In addition to this, the extent of 
the diffusion of the antimicrobial compound on the bioassay plates suggests that the compound is 
water soluble due to its capacity to diffuse through the aqueous agar. 
The lack of activity in the cell free broth may indicate that the nutrient depleted conditions 
in the S1 fermentation broth failed to induce the production of antimicrobial secondary 
metabolites, the antimicrobial activity observed on the bioassay plates after an extended incubation 
may have provided these nutrient limited conditions stimulating the production of these 
metabolites. This achievement of nutrient depleted conditions stimulating the production of 
secondary metabolism on the bioassay plate but not in the fermentation broth is consistent with 
the observations of gradual diffusion and development of the antimicrobial compound on the 
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bioassay plate. Similarly, the observation that no antibacterial activity was exhibited in cell free 
variations of the fermentation broth also supports this conclusion, as in the absence of cells, the 
induction of secondary metabolism cannot be achieved. An alternative interpretation of the results 
above describes an antimicrobial compound being produced by Streptomyces S1 in a manner that 
is attached to the outer cell surface, preventing the isolation of antimicrobial activity in a cell free 
environment. This interpretation of the experimental data would explain the diffusion of the 
antimicrobial activity as the result of the growth of hyphae through the agar giving this diffuse 
zone of inhibition. This interpretation could be tested through the bioassaying of a fermentation 
broth of S1 after the constituent bacteria’s outer cellular surface has been disrupted. 
The results of the MALDI-MS analysis of the 30-day fermentation broth produced signals 
not observed in the R2A background media. This is to be expected as the result of normal microbial 
metabolism however due to the inability to correlate any antimicrobial activity to the cell free 
fermentation broth. The spectra obtained appeared quite noisy potentially due to signals detected 
from the ionized HCCA matrix and matrix adducts of sodium or potassium. 
CONCLUSIONS AND FUTURE WORK 
 The results of this research leave many questions to be answered, and could open up doors 
to new potential research questions. The observation that antimicrobial activity consistently failed 
to be observed in the cell free fermentation broth despite being produced on the plate opens the 
opportunity to further fine-tune fermentation conditions so as to produce the antimicrobial 
secondary metabolites in solution allowing for their extraction and for further analysis to take 
place. In future applications of MALDI to the analysis of such complex mixtures blanks should 
include several replicates of matrix only prepared with hard water to evaluate the presence of any 
matrix salts to prevent these signals from confounding results. Another addition to the MALDI 
sample preparation protocol is the matrix suppressor cetyltrimethylammonium bromide (CTAB) 
which through the suppression of the HCCA matrix could improve resolution (Gou et al. 2002).  
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APPENDICES 
Oxoid Nutrient Agar Media 
1.0g/L Lab-Lemco powder 
2.0g/L Yeast extract 
5.0g/L Peptone 
5.0g/L Sodium chloride 
15g/L Agar 
pH 7.4 
Oxoid Nutrient Broth Media 
1.0g/L Lab-Lemco powder 
2.0g/L Yeast extract 
5.0g/L Peptone 
5.0g/L Sodium chloride 
pH 7.4 
R2A Broth Media 
0.500g/L Casein acid hydrolysate 
0.500g/L Yeast extract 
0.500g/L Peptone 
0.500g/L Dextrose 
0.500g/L Starch, soluble 
0.300g/L Dipotassium phosphate 
0.024g/L Magnesium sulphate 
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0.300g/L Sodium pyruvate 
pH 7.2 
V8 Broth Media 
200mL reduced salt V8 juice supernatant (centrifuged at 5000rpm for 10 minutes) 
3.0g/L Calcium carbonate 
pH 7.4 
Hickey Tresnar Broth Media 
1.0g/L Yeast extract 
1.0g/L Beef extract 
2.0g/L N2 Amine 
10.0g/L Dextrin 
pH 7.5 
Table 2. Reagents used. 
Reagent and Grade Distributor 
HPLC grade hexane Sigma Aldrich 
LC grade ethyl acetate Sigma Aldrich 
Reagent grade trifluoroacetic acid Sigma Aldrich 
Reagent grade acetonitrile Sigma Aldrich 
18MΩ water - 
Reagent grade 2-Propanol Fischer Scientific 
Α-Cyano-4-hydroxycinnamic acid Bruker Daltonics 
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Table 2. MALDI M/Z signal unique to the S1 30 day fermentation broth, obtained from the systematic comparison with R2A 
background spectra 
Unique 30 Day Broth MS Signals 
236.881 
244.738 
246.72 
247.572 
250.708 
253.578 
256.465 
262.4 
263.463 
264.344 
274.14 
276.246 
285.965 
293.681 
301.795 
301.816 
311.354 
327.263 
329.239 
338.211 
372.196 
373.339 
420.557 
608.043 
623.675 
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Table 3. Tabulated R2A background peaks. Red shaded cells indicate peaks duplicated in more than one replicate. 
 
R2A Background 
1
R2A Background 
2
R2A Background 
3
R2A Background 
4
R2A Background 
5
R2A Background 
6
R2A background 
Consistent
203.492 203.492 203.492 203.492 203.492 203.492 203.492
219.299 219.352 219.305 219.318 219.437 219.305 219.305
227.819 228.085 227.819 227.819 219.437 228.085 219.437
230.817 230.823 230.822 230.822 230.823 230.823 227.819
231.642 231.918 231.918 231.908 231.918 231.918 228.085
232.746 234.953 232.746 232.746 232.746 232.746 230.822
233.642 236.87 233.756 234.952 234.952 234.953 231.918
234.952 237.727 234.952 235.784 235.784 235.784 232.746
236.616 238.835 236.616 236.696 236.708 236.72 234.952
237.727 239.68 237.728 237.728 237.727 237.727 235.784
238.563 242.755 238.563 238.563 238.68 238.673 236.616
242.483 243.609 239.679 239.679 239.68 239.68 237.727
258.205 258.338 242.483 242.483 242.605 242.593 238.563
259.186 259.368 243.608 243.608 243.608 243.609 239.68
260.243 260.243 254.443 258.205 253.576 258.205 242.483
262.289 262.29 258.205 259.368 254.443 259.368 243.608
273.844 274.138 259.363 260.243 258.205 260.243 254.443
274.842 275.043 260.243 262.29 259.368 262.29 258.205
275.945 275.945 262.29 273.948 260.243 273.977 259.368
276.915 277.148 273.844 275.043 262.29 275.043 260.243
301.504 301.504 275.038 275.945 271.155 275.945 262.29
314.376 314.56 275.945 276.989 273.977 277.148 273.844
315.333 315.532 276.947 278.054 275.043 278.054 273.977
341.567 339.208 281.996 281.996 275.945 301.504 275.043
354.475 341.901 301.504 301.504 276.976 314.56 275.945
384.978 382.289 314.553 314.553 278.054 315.532 277.148
385.746 384.979 315.528 315.523 301.504 341.901 278.054
419.432 386.054 341.891 341.891 314.558 354.475 281.996
422.429 387.128 382.118 354.475 315.528 379.263 301.504
445.716 403.845 384.979 382.119 341.894 382.118 314.56
465.219 406.789 386.053 384.978 354.475 384.979 315.532
466.48 419.432 403.841 386.053 369.035 386.054 341.891
481.272 422.436 419.432 403.844 382.119 392.903 341.901
602.126 446.1 422.435 419.432 384.978 394.715 354.475
657.949 449.984 445.851 445.717 386.052 403.845 382.118
673.766 465.687 465.672 449.978 403.844 406.789 384.979
689.785 466.607 466.48 465.684 406.77 408.636 386.053
481.273 481.273 466.589 419.432 419.432 403.844
497.132 483.29 481.273 422.435 422.435 406.789
658.424 674.22 658.424 446.083 446.083 419.432
674.248 689.785 674.245 449.98 465.687 422.435
690.267 705.812 689.785 465.684 466.48 446.083
706.005 693.188 466.585 481.273 465.684
706.002 481.273 658.425 465.687
658.418 674.248 466.48
674.246 689.785 481.273
689.785 706.005 658.424
692.221 674.248
706.002 689.785
708.937 706.002
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Table 4. Tabulated 30 day fermentation broth peaks. Yellow shaded cells indicate peaks duplicated in more than one replicate. 
 
Broth 1 Broth 2 Broth 3 Broth 4 Broth 5 Broth 6
Consistent 
Signals
236.887 225.645 230.823 236.881 236.616 236.738 230.823
239.825 230.823 236.883 237.727 237.728 237.728 236.881
242.762 236.888 237.727 239.953 246.714 242.483 236.888
244.738 242.76 239.945 244.737 247.572 246.719 237.727
246.72 246.72 242.756 246.72 258.312 247.572 242.76
250.708 258.374 244.738 247.572 262.29 253.578 244.738
256.465 259.368 246.72 250.708 263.169 256.465 246.72
258.385 262.582 247.572 253.578 264.344 258.205 247.572
259.368 268.182 250.708 256.465 274.142 262.29 250.708
262.443 274.141 253.578 258.325 275.044 264.344 253.578
268.474 275.043 256.465 259.369 276.246 274.13 256.465
274.14 276.246 258.333 262.397 277.15 275.043 259.368
275.044 277.15 259.369 263.463 278.055 276.246 262.29
276.247 281.996 262.4 264.344 293.681 277.15 262.4
277.15 292.129 263.462 270.261 301.504 278.055 263.463
278.055 301.819 264.344 274.138 311.354 293.681 264.344
281.996 311.674 274.14 275.044 314.556 301.504 274.14
285.966 314.567 275.044 276.246 315.523 311.354 275.043
301.816 315.534 276.231 277.15 338.21 314.566 276.246
311.657 317.473 278.055 278.055 338.993 315.534 277.15
314.567 338.211 285.965 285.965 372.196 338.198 278.055
315.534 339.216 301.801 301.795 373.252 372.196 281.996
372.528 372.547 311.526 311.512 403.844 373.31 285.965
373.354 481.273 314.567 314.567 404.58 403.845 293.681
399.084 689.784 315.534 315.534 419.432 409.744 301.504
419.432 327.263 327.263 420.545 419.77 301.795
420.557 329.239 329.239 421.307 420.557 301.816
449.984 372.525 353.789 481.273 481.273 311.354
465.687 373.339 372.519 497.131 497.131 314.567
608.041 373.339 598.951 623.675 315.534
624.131 403.845 623.675 327.263
409.746 631.569 329.239
419.432 674.249 338.211
481.273 690.271 372.196
608.043 706.005 373.339
624.119 721.928 403.845
706.005 419.432
420.557
481.273
497.131
608.043
623.675
706.005
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Figure 6. R2A background MS replicate 1 
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Figure 7. R2A background MS replicate 2 
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Figure 8 R2A background MS replicate 3 
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Figure 9 R2A background MS replicate 4 
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Figure 10 R2A background MS replicate 5 
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Figure 11 R2A background MS replicate 6 
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Figure 12 S1 30 day fermentation broth MS replicate 1 
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Figure 13 S1 30 day fermentation broth MS replicate 2 
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Figure 14 S1 30 day fermentation broth MS replicate 3 
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Figure 15 S1 30 day fermentation broth MS replicate 4 
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Figure 16 S1 30 day fermentation broth MS replicate 5 
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Figure 17 S1 30 day fermentation broth MS replicate 6 
